Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Other Current Liabilities

Last Annual Value

3.18M

3-Year CAGR

94%

5-Year CAGR

39%

10-Year CAGR

91%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Other Current Liabilities

NAUT · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.18M
2.3%52.3%N/A 
8.56M
-2.6%9.7%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
12.41M
117.8%114.7%N/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
10.54M
25.8%20.7%N/A
19.68M
2.1%-15.7%48.8%
3.71M
88.3%82.2%N/A
8.13M
27.9%22.8%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
83.11M
-16.2%1.9%29.3%
11.99M
117.5%37.1%N/A
5.38M
101.1%128.9%N/A
5.72M
246.9%65.8%67.4%
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58